16.13USD-0.28%Mkt Cap: 470.24M $P/E: —Today
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clin…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap470.24M $
Enterprise Value205.62M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-60.55M $
Revenue/Share—
Last Price16.13 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees63
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-2.77
EV/Revenue—
P/S—
P/B-0.27
EPS (TTM)-3.33
EPS (Forward)—
52W Range
15.2544% of range17.25
52W High17.25 USD
52W Low15.25 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE45.97%
ROA-37.16%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-46.92M $
CapEx (TTM)1.07M $
FCF Margin—
FCF Yield—
Net Debt-92.98M $
Net Debt/EBITDA1.25
Balance Sheet
Debt/Equity-0.17
Current Ratio7.40
Quick Ratio7.17
Book Value/Sh-57.5270 USD
Cash/Share43.87 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.29.08M
Float1.64M
Insiders13.18%
Institutions20.65%
Technical
SMA 5016.17 (-0.3%)
SMA 20016.17 (-0.3%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)507.35K
Avg Vol (10d)458.20K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—